GLP-1 analogues: A new therapeutic approach to prevent ductopenia in cholangiopathies?

Gut

Volumn 58, Issue 7, 2009, Pages 902-903

  Beuers, Ulrich ^a   Göke, Burkhard ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36]; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TAURINE CONJUGATED URSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID DERIVATIVE;

BILE DUCT DISEASE; CELL PROLIFERATION; CELL PROTECTION; CELL TRANSDIFFERENTIATION; CELL TYPE; CHOLANGIOCYTE; CHOLESTASIS; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DUCTOPENIA; GLUCAGON RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN LIKE ACTIVITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PANCREAS CELL; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; STOMACH EMPTYING; VOMITING;

BILE DUCT DISEASES; CELL PROLIFERATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; PEPTIDES; URSODEOXYCHOLIC ACID; VENOMS;

EID: 67649635785     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.165688     Document Type: Note

References (14)

1. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902;28:325-353
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157 (Pubitemid 46711096)
3. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-19655
4. Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology 2007;133:244-255 (Pubitemid 47031126)
5. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007;132:415-431 (Pubitemid 46108729)
6. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004;127:1565-1577 (Pubitemid 39457780)
7. Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 2009;58:990-997
8. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720 (Pubitemid 43374522)
9. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract 2006;3:318-328 (Pubitemid 43842248)
10. Rodrigues CM, Sola S, Sharpe JC, et al. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry 2003;42:3070-3080 (Pubitemid 36331552)
11. Schoemaker MH, Conde de la Rosa L, Buist-Homan M, et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 2004;39:1563-1573 (Pubitemid 38702657)
12. 2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol 2006;168:398-409.
13. Wimmer R, Hohenester S, Pusl T, et al. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver. Gut 2008;57:1448-1454
14. Beuers U. Crosstalk of liver, bile ducts and the gut. Clin Rev Allergy Immunol 2009;36:1-3.